{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:03:43Z","timestamp":1791194623555,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T00:00:00Z","timestamp":1260489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of the present study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) concomitantly or concurrently used psychotropic drugs and analgesics and the association between this drug use and the patients' gender and age. An additional aim was to investigate the sequence of drug therapy among users of both antiobesity drugs and antidepressants or antipsychotics, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were retrieved from the Norwegian Prescription Database (NorPD). All patients who had an antiobesity drug (ATC code A08A) dispensed from a Norwegian pharmacy between January 2004 and December 2007 were included in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One in four patients using antiobesity drugs had at least on one occasion used a psychotropic drug concomitantly. The most commonly used psychotropic drugs were anxiolytics\/hypnotics\/sedatives (17.7%) and antidepressants (14.7%). Analgesics were used by 36.2%. A significantly higher percentage of women used anxiolytics\/hypnotics\/sedatives (18.8% <jats:italic>vs.<\/jats:italic> 14.0%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0005), antidepressants (16.1% <jats:italic>vs.<\/jats:italic> 9.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0005), antipsychotics (4.0% <jats:italic>vs.<\/jats:italic> 2.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0005) and analgesics (37.8% <jats:italic>vs.<\/jats:italic> 30.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0005) concomitantly with antiobesity drugs when compared to men. One out of ten patients using sibutramine had at least on one occasion used an interacting drug concomitantly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Use of psychotropic drugs and analgesics among patients using antiobesity drugs is extensive, especially among women. Clinicians prescribing sibutramine should be more aware of drug interactions with other prescribed drugs. There is still insufficient information on psychiatric disorders among these patients. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1896","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T11:06:45Z","timestamp":1260529605000},"page":"273-279","source":"Crossref","is-referenced-by-count":5,"title":["Use of psychotropic drugs and analgesics among users of antiobesity drugs\u2014a population based study"],"prefix":"10.1002","volume":"19","author":[{"given":"Merethe Omdal","family":"Amundsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Engdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"WHO.2006;Obesity and overweight. What are overweight and obesity?http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/index.html(accessed 30 January 2008)."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-14"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.268"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/10640260802714654"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.12.009"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.02089.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-132"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-163"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.117.1.3"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1037\/0278-6133.12.5.342","article-title":"Obese people who seek treatment have different characteristics than those who do not seek treatment","volume":"12","author":"Fitzgibbon ML","year":"1993","journal-title":"Health Psychol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2006.03.016"},{"key":"e_1_2_1_13_2","first-page":"743","article-title":"The impact of obesity on drug prescribing in primary care","volume":"55","author":"Counterweight Project Team","year":"2005","journal-title":"Br J Gen Pract"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-7-43"},{"key":"e_1_2_1_15_2","unstructured":"The Norwegian Medicines Agency.SPC \u2013 Orlistat.http:\/\/www.legemiddelverket.no\/custom\/templates\/gzInterIFrame____61197.aspx(accessed 05 February2008)."},{"key":"e_1_2_1_16_2","unstructured":"The Norwegian Medicines Agency.SPC \u2013 Sibutramine.http:\/\/www.legemiddelverket.no\/custom\/templates\/gzInterIFrame____61197.aspx(accessed 05 February2008)."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.413113.25"},{"key":"e_1_2_1_18_2","unstructured":"The Norwegian Medicines Agency.SPC \u2013 Rimonabant.http:\/\/www.legemiddelverket.no\/custom\/templates\/gzInterIFrame____61197.aspx(accessed 05 February2008)."},{"key":"e_1_2_1_19_2","unstructured":"EMEA.The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia2008.http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/acomplia\/53777708en.pdf(accessed 24 October 2008)."},{"key":"e_1_2_1_20_2","unstructured":"EMEA.Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) 2008.http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/acomplia\/53715308en.pdf(accessed 16 February 2009)."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm044"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124010-00005"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0226-8"},{"issue":"1","key":"e_1_2_1_24_2","first-page":"S143","article-title":"Factors associated with prescription of obesity medications in the US","volume":"17","author":"Pokras SM","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"e_1_2_1_25_2","first-page":"S142","article-title":"Utilization and patient experience with obesity prescriptions in the US","volume":"17","author":"Pokras SM","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_1_26_2","volume-title":"Rapport 2008: The Norwegian Prescription Database 2004\u20132007","author":"R\u00f8nning M","year":"2008"},{"key":"e_1_2_1_27_2","volume-title":"Guidelines for ATC Classification and DDD Assignment","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2007"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1304"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00005"},{"key":"e_1_2_1_30_2","first-page":"34","article-title":"Has the obesity epidemic reached Norway?","volume":"127","author":"Ulset E","year":"2007","journal-title":"Tidsskr Nor L\u00e6geforen"},{"key":"e_1_2_1_31_2","unstructured":"Ministry of Health and Care Services.Women's health in Norway. Chapter 1.9: Gender perspectives on health services and \u2013consumptions. NOU 1999:13. Text in Norwegian."},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp08X319710"},{"key":"e_1_2_1_33_2","volume-title":"Drug consumption in Norway 2003\u20102007","author":"R\u00f8nning M","year":"2008"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802401"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1896","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1896","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:58:31Z","timestamp":1700582311000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1002\/pds.1896"],"URL":"https:\/\/doi.org\/10.1002\/pds.1896","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}